Variants affecting diverse domains of MEPE are associated with two distinct bone disorders, a craniofacial bone defect and otosclerosis.
Adult
Bone and Bones
/ metabolism
Extracellular Matrix Proteins
/ genetics
Facial Paralysis
/ congenital
Family
Female
Genetic Diseases, X-Linked
/ genetics
Genetic Variation
/ genetics
Glycoproteins
/ genetics
Hearing Loss
/ genetics
Heterozygote
Humans
Male
Otosclerosis
/ genetics
Pedigree
Phenotype
Phosphoproteins
/ genetics
Exome Sequencing
/ methods
MEPE
craniofacial bone disorder
hearing loss
hereditary congenital facial paresis
otosclerosis
Journal
Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
03
04
2018
accepted:
31
08
2018
pubmed:
6
10
2018
medline:
14
2
2020
entrez:
6
10
2018
Statut:
ppublish
Résumé
To characterize new molecular factors implicated in a hereditary congenital facial paresis (HCFP) family and otosclerosis. We performed exome sequencing in a four-generation family presenting nonprogressive HCFP and mixed hearing loss (HL). MEPE was analyzed using either Sanger sequencing or molecular inversion probes combined with massive parallel sequencing in 89 otosclerosis families, 1604 unrelated affected subjects, and 1538 unscreened controls. Exome sequencing in the HCFP family led to the identification of a rare segregating heterozygous frameshift variant p.(Gln425Lysfs*38) in MEPE. As the HL phenotype in this family resembled otosclerosis, we performed variant burden and variance components analyses in a large otosclerosis cohort and demonstrated that nonsense and frameshift MEPE variants were significantly enriched in affected subjects (p = 0.0006-0.0060). MEPE exerts its function in bone homeostasis by two domains, an RGD and an acidic serine aspartate-rich MEPE-associated (ASARM) motif inhibiting respectively bone resorption and mineralization. All variants associated with otosclerosis are predicted to result in nonsense mediated decay or an ASARM-and-RGD-truncated MEPE. The HCFP variant is predicted to produce an ASARM-truncated MEPE with an intact RGD motif. This difference in effect on the protein corresponds with the presumed pathophysiology of both diseases, and provides a plausible molecular explanation for the distinct phenotypic outcome.
Identifiants
pubmed: 30287925
doi: 10.1038/s41436-018-0300-5
pii: S1098-3600(21)01476-3
doi:
Substances chimiques
Extracellular Matrix Proteins
0
Glycoproteins
0
MEPE protein, human
0
Phosphoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1199-1208Références
Menger DJ, Tange RA. The aetiology of otosclerosis: a review of the literature. Clin Otolaryngol Allied Sci. 2003;28:112–120.
doi: 10.1046/j.1365-2273.2003.00675.x
Kremer H, Kuyt LP, van den Helm B, et al. Localization of a gene for Mobius syndrome to chromosome 3q by linkage analysis in a Dutch family. Hum Mol Genet. 1996;5:1367–1371.
doi: 10.1093/hmg/5.9.1367
Michielse CB, Bhat M, Brady A, et al. Refinement of the locus for hereditary congenital facial palsy on chromosome 3q21 in two unrelated families and screening of positional candidate genes. Eur J Hum Genet. 2006;14:1306–1312.
doi: 10.1038/sj.ejhg.5201706
Verzijl HT, van den Helm B, Veldman B, et al. A second gene for autosomal dominant Mobius syndrome is localized to chromosome 10q, in a Dutch family. Am J Hum Genet. 1999;65:752–756.
doi: 10.1086/302539
Webb BD, Shaaban S, Gaspar H, et al. HOXB1 founder mutation in humans recapitulates the phenotype of Hoxb1-/- mice. Am J Hum Genet. 2012;91:171–179.
doi: 10.1016/j.ajhg.2012.05.018
Uyguner ZO, Toksoy G, Altunoglu U, Ozgur H, Basaran S, Kayserili H. A new hereditary congenital facial palsy case supports arg5 in HOX-DNA binding domain as possible hot spot for mutations. Eur J Med Genet. 2015;58:358–363.
doi: 10.1016/j.ejmg.2015.05.003
Sahin Y, Gungor O, Ayaz A, et al. A novel homozygous HOXB1 mutation in a Turkish family with hereditary congenital facial paresis. Brain Dev. 2017;39:166–170.
doi: 10.1016/j.braindev.2016.09.002
Vogel M, Velleuer E, Schmidt-Jimenez LF, et al. Homozygous HOXB1 loss-of-function mutation in a large family with hereditary congenital facial paresis. Am J Med Genet A. 2016;170:1813–1819.
doi: 10.1002/ajmg.a.37682
Tomas-Roca L, Tsaalbi-Shtylik A, Jansen JG, et al. De novo mutations in PLXND1 and REV3L cause Mobius syndrome. Nat Commun. 2015;6:7199.
doi: 10.1038/ncomms8199
Milroy CM, Michaels L. Pathology of the otic capsule. J Laryngol Otol. 1990;104:83–90.
doi: 10.1017/S0022215100111946
Declau F, Van Spaendonck M, Timmermans JP, et al. Prevalence of otosclerosis in an unselected series of temporal bones. Otol Neurotol. 2001;22:596–602.
doi: 10.1097/00129492-200109000-00006
Moumoulidis I, Axon P, Baguley D, Reid E. A review on the genetics of otosclerosis. Clin Otolaryngol. 2007;32:239–247.
doi: 10.1111/j.1365-2273.2007.01475.x
Schrauwen I, Van Camp G. The etiology of otosclerosis: a combination of genes and environment. Laryngoscope. 2010;120:1195–1202.
pubmed: 20513039
Ziff JL, Crompton M, Powell HR, et al. Mutations and altered expression of SERPINF1 in patients with familial otosclerosis. Hum Mol Genet. 2016;25:2393–2403.
pubmed: 27056980
pmcid: 5181625
Untergasser A, Cutcutache I, Koressaar T, et al. Primer3—new capabilities and interfaces. Nucleic Acids Res. 2012;40:e115.
doi: 10.1093/nar/gks596
Ockeloen CW, Khandelwal KD, Dreesen K, et al. Novel mutations in LRP6 highlight the role of WNT signaling in tooth agenesis. Genet Med. 2016;18:1158–1162.
doi: 10.1038/gim.2016.10
Boyle EA, O’Roak BJ, Martin BK, Kumar A, Shendure J. MIPgen: optimized modeling and design of molecular inversion probes for targeted resequencing. Bioinformatics. 2014;30:2670–2672.
doi: 10.1093/bioinformatics/btu353
O’Roak BJ, Vives L, Fu W, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012;338:1619–1622.
doi: 10.1126/science.1227764
Hiatt JB, Pritchard CC, Salipante SJ, O’Roak BJ, Shendure J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 2013;23:843–854.
doi: 10.1101/gr.147686.112
San Lucas FA, Wang G, Scheet P, Peng B. Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics. 2012;28:421–422.
doi: 10.1093/bioinformatics/btr667
Wang GT, Peng B, Leal SM. Variant association tools for quality control and analysis of large-scale sequence and genotyping array data. Am J Hum Genet. 2014;94:770–783.
doi: 10.1016/j.ajhg.2014.04.004
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12:7–8.
doi: 10.1038/nmeth.3213
Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–1612.
doi: 10.1002/jcc.20084
Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291.
doi: 10.1038/nature19057
Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res. 2003;44 Suppl 1:33–40.
doi: 10.1080/03008200390152061
Martin A, David V, Laurence JS, et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology. 2008;149:1757–1772.
doi: 10.1210/en.2007-1205
David V, Martin A, Hedge AM, Rowe PS. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology. 2009;150:4012–4023.
doi: 10.1210/en.2009-0216
Nampei A, Hashimoto J, Hayashida K, et al. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab. 2004;22:176–184.
doi: 10.1007/s00774-003-0468-9
Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics. 2000;67:54–68.
doi: 10.1006/geno.2000.6235
Ogbureke KU, Fisher LW. Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res. 2004;83:664–670.
doi: 10.1177/154405910408300902
Ogbureke KU, Fisher LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int. 2005;68:155–166.
doi: 10.1111/j.1523-1755.2005.00389.x
Gowen LC, Petersen DN, Mansolf AL, et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003;278:1998–2007.
doi: 10.1074/jbc.M203250200
Zelenchuk LV, Hedge AM, Rowe PS. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif. Bone. 2015;79:131–142.
doi: 10.1016/j.bone.2015.05.030
Rowe PS, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004;34:303–319.
doi: 10.1016/j.bone.2003.10.005
Sprowson AP, McCaskie AW, Birch MA. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion. J Orthop Res. 2008;26:1256–1262.
doi: 10.1002/jor.20606
Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44:491–501.
doi: 10.1038/ng.2249
Neu-Yilik G, Amthor B, Gehring NH, et al. Mechanism of escape from nonsense-mediated mRNA decay of human beta-globin transcripts with nonsense mutations in the first exon. RNA. 2011;17:843–854.
doi: 10.1261/rna.2401811
van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S, Lowik C. Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation. J Bone Miner Res. 1994;9:1021–1028.
doi: 10.1002/jbmr.5650090709
Hayashibara T, Hiraga T, Yi B, et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res. 2004;19:455–462.
doi: 10.1359/JBMR.0301263